| Project/Area Number |
16K11030
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Toho University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2016-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
|
|---|
| Keywords | 前立腺癌 / 去勢抵抗性前立腺癌 / ホルモン療法 / プロテオミクス / アンドロゲン受容体 / アビラテロン / エンザルタミド / 骨転移 / 酢酸アビラテロン / アルカリフォスファターゼ / 分子標的薬 / 分子診断 / ドセタキセル / アンドロゲン除去療法 / 前立腺特異抗原（PSA） / PSAフレア / 前立腺特異抗原(PSA) / オーダーメイド医療 / 遺伝子多型 / ノモグラム |
|---|
| Outline of Final Research Achievements |
In the treatment system for prostate cancer, hormone therapy is widely used not only as the main treatment but also as an adjuvant / combination therapy. The biggest obstacle to hormone therapy is the development of the condition by the acquisition of hormone therapy resistance in cancer cells. Especially in recent years, the importance of the androgen-androgen receptor system has been reaffirmed.
Under these circumstances, in order to provide tailor-made hormone therapy for selecting the optimal treatment method for each patient, in basic research, focusing on the search for the causative protein, in addition to conventional biomarkers, We also analyzed genomic markers such as gene polymorphisms. We also reported clinically including the molecular functional diagnosis of advanced prostate cancer and the report of clinical trial data of new drugs.
|
| Academic Significance and Societal Importance of the Research Achievements |
前立腺癌は、高齢化社会の到来や生活習慣の欧米化もあって、日本においても急増しており、特に発症頻度では男性の悪性腫瘍の上位に位置している。日本の新規前立腺癌患者の約15%程度は転移病期で診断される事から、医学的にも、社会的にも、進行性前立腺癌の病態解明や診断・治療の進歩が急務である。本研究では、進行性前立腺癌の治療体系において、最も重要な選択肢のひとつであるホルモン療法の（去勢）抵抗性の分子生物学的解明と、その治療への応用を目指した、実践的な研究と考える。
|
